Ahn Jeeyun, Wee Won Ryang, Lee Jin Hak, Hyon Joon Young
Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Korean J Ophthalmol. 2011 Oct;25(5):355-7. doi: 10.3341/kjo.2011.25.5.355. Epub 2011 Sep 20.
We report a case of vortex keratopathy in a patient treated with vandetanib for non-small cell lung cancer (NSCLC). A 44-year-old female who underwent two cycles of chemotherapy for NSCLC complained of visual blurring in both eyes after the initiation of vandetanib, an anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor. On ophthalmic examination, visual acuities were 20 / 20 OU and, with the exception of diffuse vortex keratopathy in both eyes, other findings were unremarkable. Vandetanib is believed to have caused vortex keratopathy in this patient. Anti-EGFR properties affecting normal corneal epithelial cell migration and wound healing or drug associated metabolite deposition, which is the case in numerous drug-associated vortex keratopathies, may be possible underlying mechanisms in the formation of this corneal complication.
我们报告了一例使用凡德他尼治疗非小细胞肺癌（NSCLC）的患者发生涡状角膜病变的病例。一名44岁女性因NSCLC接受了两个周期的化疗，在开始使用凡德他尼（一种抗表皮生长因子受体（EGFR）和抗血管内皮生长因子受体2蛋白酪氨酸激酶抑制剂）后，抱怨双眼视力模糊。眼科检查显示，双眼视力均为20/20，除双眼弥漫性涡状角膜病变外，其他检查结果均无异常。据信，凡德他尼导致了该患者的涡状角膜病变。影响正常角膜上皮细胞迁移和伤口愈合的抗EGFR特性或药物相关代谢产物沉积，在许多药物相关性涡状角膜病变中都是如此，可能是这种角膜并发症形成的潜在机制。
